Skip to main content

Table 6 Sensitivity analysis of the incremental cost effectiveness of pregabalin versus gabapentin in the treatment of painful diabetic neuropathy and post herpetic neuralgia

From: Pregabalin versus gabapentin in the management of peripheral neuropathic pain associated with post-herpetic neuralgia and diabetic neuropathy: a cost effectiveness analysis for the Greek healthcare setting

Parameter Baseline Sensitivity analysis Cost per additional day with no or mild pain Cost per QALY gained
Gabapentin dose (mg) 2400 1800 14 (8,19) 23 786 (14266,33498)
Gabapentin dose (mg) 2400 1200 16 (9,24) 30 241 (18086,44056)
Costs considered All healthcare costs Medication cost only 16 (14,18) 25 683 (22812,29829)
Pregabalin daily cost 3.65 ↑20% 24 (18,34) 39 063 (28704,54620)
Pregabalin daily cost 3.65 ↓20% 7 (2,14) 11 075 (2944,23040)
Weekly probability of PCP visit in relation to NeP No/mild: 0.25 ↑20% 14 (8,20) 21 025 (11592,30710)
Moderate: 0.31
Severe: 0.48
Weekly probability of PCP visit in relation to NeP No/mild: 0.25 ↓20% 13 (7,19) 19 773 (10531,28687)
Moderate: 0.31
Severe: 0.48
Health utility associated with pain severity No/mild: 0.64 ↑20% 13 (9,18) 17 017 (10296,23936)
Moderate: 0.48
Severe: 0.27
Health utility associated with pain severity No/mild: 0.64 ↓20% 14 (8,20) 27 505 (15418,40596)
Moderate: 0.48
  Severe: 0.27    
  1. Mean values in € (SE) 95% CI.
  2. NeP – Neuropathic pain.
  3. PCP – primary care physician.
Back to article page

BMC Neurology

ISSN: 1471-2377

Contact us